Core Viewpoint - The company highlights the potential applications of microwave radio frequency technology in the biomedical field, particularly in wireless signal transmission for brain-computer interfaces, while acknowledging the technical challenges that need to be overcome [1] Group 1: Technology and Applications - Microwave radio frequency technology is identified as a key method for signal transmission and processing, with broad potential applications in biomedical fields [1] - The company’s subsidiaries, Kuanpu Technology and Renjian Microwave, have extensive experience in developing and manufacturing RF microwave components for specialized applications, focusing on high reliability, miniaturization, and low loss [1] Group 2: Challenges and Future Directions - Practical applications of this technology in brain-computer interfaces face multiple technical challenges, including weak signal transmission, interference suppression, biocompatibility, and safety [1] - The company has not yet commercialized any brain-computer interface products but plans to closely monitor advancements in frontier technologies and explore cross-domain collaboration opportunities based on its core technological advantages [1]

Investment Rating - The report gives a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26][32]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 3.61% from December 26, 2025, to January 8, 2026, exceeding the CSI 300 index by approximately 1.56 percentage points [12]. - Most sub-sectors within the industry recorded positive returns during the same period, with the hospital and medical R&D outsourcing sectors leading with increases of 10.62% and 7.39%, respectively [13]. - Approximately 82% of stocks in the industry achieved positive returns, with notable performers including Xiangyu Medical, which saw a weekly increase of 57.50% [14][17]. - The overall industry valuation has risen, with the SW pharmaceutical and biotechnology index's PE (TTM) at approximately 52.75 times, which is 3.78 times higher than the CSI 300 index [18][26]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 3.61% from December 26, 2025, to January 8, 2026 [12]. - Most sub-sectors recorded positive returns, particularly hospitals and medical R&D outsourcing, which increased by 10.62% and 7.39%, respectively [13]. - About 82% of stocks in the industry had positive returns, with significant gains from several companies [14]. 2. Industry News - The report highlights the acceleration of volume-based procurement in 2026, with various local and national initiatives underway to streamline drug procurement processes [24]. - A new batch of encouraged generic drugs has been announced, focusing on optimizing the drug supply system and enhancing the availability of essential medications [23]. 3. Company Announcements - Jiangsu Yahui Pharmaceutical announced the completion of the first patient enrollment in a Phase I clinical trial for its drug APL-2401, targeting advanced solid tumors [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, particularly following announcements from Neuralink regarding large-scale production plans [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28][29].

全市场超3900只个股上涨，连续2日超百股涨停。沪深两市成交额3.12万亿元，较上一个交易日放量3224亿， 历史第五次突破3万亿。 2026年，A股不仅在第一天收获"开门红"，连第一周整体也是红彤彤的。 数据显示，沪指本周累涨3.82%，完成了从3983点到4121点的跨越。 量价齐升的情况也很显著。本周前四天，全市场成交额连续超过2.5万亿元，周五则直接飙升至3.15万亿元， 时隔73个交易日后再度站上3万亿大关。 1月9日，市场震荡拉升，沪指高开高走突破4100点，深成指涨超1%。截至收盘，沪指涨0.92%，深成指涨 1.15%，创业板指涨0.77%。 板块来看，AI应用、商业航天、可控核聚变等概念领涨。下跌方面，脑机接口概念下挫。 行情软件显示，早间9:43开始，富时A50期指曾有一波急速拉升，A股随之由震荡转为持续1小时的单边上 行，沪指则趁势突破了4100点关口。 结合消息面来看，这里大概率是国家统计局公布的CPI和PPI数据，提振了市场信心。 年前的你，可曾预想到这般走势？ 实际上，这样"可遇不可求"的超预期表现，本来就不必去预判，反而应该学会"跟随"。还是以沪指迄今走出 的"16连阳"为例： ...

今日A股市场震荡拉升， 沪指高开高走突破4100点 ，深成指涨超1%。沪深两市成交额3.12万亿，较上一个交易日放量3224亿，时隔73个交易日后再 度站上3万亿大关，历史第五次突破3万亿。 盘面上，市场热点快速轮动， 全市场超3900只个股上涨，连续2日超百股涨停 。从板块来看， AI应用概念集体爆发 ，二十余只成分股涨停，引力传 媒5天4板，省广集团、会畅科技、粤传媒、易点天下涨停。商业航天概念反复活跃，鲁信创投11天9板，中国卫通9天5板，金风科技4连板，航天电 子6天4板。可控核聚变概念延续强势，弘讯科技、中国一重双双3连板。 下跌方面，脑机接口概念下挫，美好医疗、倍益康跌超10%。 下载财联社APP获取更多资讯 准确 快速 权威 专业 7x24h电报 头条新闻 VIP资讯 实时盯盘 01-09 15:12:36 沪 4120.43 +37.45 +0.92% 7.30亿手 之 高 4121.72 成交量 开 4086.76 最 ​​ n ( 4082.98 最 俱 4083.62 成交额 1.29万亿 ▲ સ્ટેમ્પે 周K 月K 分钟 ▼ 王日 (0) MA5:4079.25 MA10:402 ...

Core Viewpoint - Microwave radio frequency technology has significant potential applications in brain-computer interfaces, although practical implementation faces multiple technical challenges [2]. Company Insights - New Jingang (300629.SZ) acknowledges the potential of microwave radio frequency technology in biomedical fields, particularly for wireless transmission of neural electrical signals in brain-computer interfaces [2]. - The company’s subsidiaries, Kuanpu Technology and Renjian Microwave, have extensive experience in developing and manufacturing RF microwave components for specialized applications, focusing on high reliability, miniaturization, and low loss [2]. - Currently, the company has not commercialized any brain-computer interface products but plans to monitor advancements in cutting-edge technologies and explore cross-industry collaborations based on its core technological advantages [2].

格隆汇1月9日丨中超控股(002471.SZ)在投资者互动平台表示，公司暂无产品可应用于脑机接口。 ...

转自：中国质量报 本报讯 （记者刘松瑶）近日，2025世界机器人大赛总决赛在国家历史文化名城、全国先进制造业基地 江苏省无锡市举办，共有来自中国、俄罗斯、葡萄牙、美国、墨西哥等21个国家的2.5万余名选手和指 导老师参赛。 据介绍，世界机器人大赛竞赛体系日臻完善，竞赛内容日趋丰富，竞赛规模不断提升。2025世界机器人 大赛围绕技术产业类和综合素质类设置相关竞赛项目，参赛人群覆盖全年龄段，共有20余个国家35万余 人次选手参赛。同时，大赛深耕产教融合服务，持续与高校、职业院校、科研院所、企业加强合作，逐 步构建具身智能、脑机接口等未来产业人才服务体系，为产业创新人才提供终身技能更新通道。 大赛主办方中国电子学会有关负责人表示，世界机器人大赛有效激发了机器人行业科技研发潜力，成为 推动全球创新型、应用型、技能型人才培养的重要力量。 【新闻快讯】 ...

凤凰网财经讯 1月9日，市场震荡拉升，沪指高开高走突破4100点，深成指涨超1%。截至收盘，沪指涨 0.92%，深成指涨1.15%，创业板指涨0.77%。沪深两市成交额3.12万亿，较上一个交易日放量3224亿， 时隔73个交易日后再度站上3万亿大关，历史第五次突破3万亿。 | | | | | 沪深京重要指数 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 *● | 咸新 | 招标幅% | | 涨跌 涨跌家数 | | 总手 | 现手 金额 | | 上证指数 | 4120.43 | 0.92 | 37.45 | 1638/602 | 0.00 | 7.30 7. | 91.0万 1.29万亿 | | 深证成指 | 14120.15 | 1.15 | 160.67 | 2128/687 | 0.02 | 10.1 7 | 1186万 1.83万亿 | | 北证50 | 1524.26 | 1.05 | 15.88 | 202/77 | 0.01 | 1137万 | 15.1万 298.30亿 | | 创业板指 | 3327.81 | 0 ...

Core Viewpoint - The medical device sector is experiencing significant growth, with key stocks showing strong performance and substantial capital inflow into related ETFs, indicating a bullish market sentiment in this industry [1][4]. Group 1: Market Performance - The CSI All-Medical Device Index (H30217) rose by 1.59%, with notable stocks such as Di'an Diagnostics (300244) hitting a 20% limit up, and Kingmed Diagnostics (603882) reaching a 10% limit up [1]. - The largest medical device ETF (159883) saw a 1.53% increase, with over 260 million yuan in capital inflow during the afternoon session [1]. - Over the past four days, the medical device ETF has experienced continuous net inflows, totaling 1.232 billion yuan, with an average daily net inflow of 308 million yuan [1]. Group 2: Key Stock Movements - Di'an Diagnostics (300244) closed at 21.72 yuan, with a 20% increase and a transaction volume of 2.198 billion yuan [2]. - Anbiping (688393) rose by 15.33% to 31.83 yuan, with a transaction volume of 308 million yuan [2]. - Kingmed Diagnostics (603882) increased by 10% to 33.66 yuan, with a transaction volume of 1.086 billion yuan [2]. Group 3: Technological and Policy Developments - Shenzhen Hanyu Pharmaceutical and Huawei Cloud launched a "Peptide AI Process Optimization Assistant," reducing R&D cycles by 45% and improving decision-making efficiency by 90% [3]. - Guangzhou's new plan emphasizes biomedicine and health as a key emerging industry, aiming to build high-level innovation platforms around cell and gene technology [3]. - The Beijing action plan for 2026-2027 aims for widespread application of AI products in healthcare institutions by 2027 [3]. Group 4: ETF Characteristics - The medical device ETF (159883) has the highest brain-computer interface content in the market, accounting for over 23%, and is the largest ETF focused on the medical device sector [4]. - The ETF includes a strong representation of innovative domestic companies, with over 80% of its components from the Sci-Tech Innovation Board and the Growth Enterprise Market [4]. - The Hong Kong medical ETF (159366) tracks the CSI Hong Kong Stock Connect Medical Theme Index, providing exposure to high-quality assets in the medical sector [4].

Core Insights - The brain-computer interface (BCI) sector in China's A-share market has experienced a significant surge, driven by a major funding round of approximately 2 billion RMB for BrainCo, a leading player in the field, marking it as the second-largest single financing in the global BCI sector after Neuralink [2][23][25] - The partnership between BrainCo and Lens Technology signifies a transformative shift in the BCI industry from experimental research to large-scale industrial production, indicating a convergence of soft neural signals and hard manufacturing capabilities [4][26] Company Developments - Lens Technology has positioned itself as a strategic investor and the exclusive manufacturer of core hardware modules for BrainCo, highlighting its ambition to transition from a consumer electronics supplier to a key player in the BCI market [5][27] - The collaboration between Lens Technology and BrainCo is seen as a critical move for Lens, as it seeks new growth avenues amid declining returns from traditional consumer electronics [5][27][30] Market Dynamics - The BCI market in China is projected to reach 3.83 billion RMB by 2025, with non-invasive products accounting for approximately 82% of the market share, indicating a strategic focus on safer, less invasive technologies [9][30] - BrainCo's proprietary dry electrode sensor technology has eliminated the need for conductive gels, facilitating high-precision brain signal acquisition and enabling a wide range of applications from medical to consumer products [9][30][31] Technological Advancements - BrainCo has developed a diverse product matrix, including a brain-machine interface for social communication aimed at children with autism and a sleep aid device that has received FDA certification, showcasing its commercial viability [10][31] - The collaboration between BrainCo and Lens Technology is expected to accelerate the commercialization of BCI technologies, moving beyond research to practical applications that address real-world issues [10][31] Industry Landscape - The BCI industry in China is characterized by a dual-core structure, with significant contributions from institutions in Beijing and Shanghai, fostering a competitive environment for technological advancements [11][32] - Beijing's Brain Science and Brain-like Research Institute is leading in high-throughput semi-invasive wireless brain-machine systems, while Shanghai focuses on brain mapping and clinical applications, creating a robust ecosystem for BCI development [13][35] Future Outlook - The Chinese government aims to establish a reliable BCI industry system by 2030, with plans to cultivate leading global enterprises, indicating strong institutional support for the sector [19][41] - The next three to five years are anticipated to be a period of significant industry reshuffling, with potential volatility in stock prices and technological pathways, as the market matures [20][41]